Journal of Clinical Oncology
Articles in this Issue
A multicenter prospective study to evaluate the efficacy of resection for initially unresectable hepatocellular carcinoma after atezolizumab combined with bevacizumab (the RACB study): Short-term outcomes.
521 Background: The IMbrave150 study showed that atezolizumab plus bevacizumab (atezo+bev) is superior to sorafenib in progression-free survival and overa...
Clinical-pathologic characteristics in young patients with metastatic colorectal cancer: Experience from a specialized cancer institute in Peru.
279 Background: Colorectal cancer (CRC) represents the third cause of malignant neoplasm in the world and the second in terms of mortality. CRC is a major...
EVEREST-2: A seamless phase 1/2 study of A2B694, a logic-gated Tmod chimeric antigen receptor T-cell (CAR T) therapy, in patients with pancreatic cancer (PANC) or other mesothelin (MSLN)-expressing solid tumors and human leukocyte antigen (HLA)–A*02 loss of heterozygosity (LOH).
TPS788 Background: MSLN is a desirable candidate for targeted therapy given its limited expression in normal tissues and its overexpression in several mal...
Impact of inpatient palliative care consultation on end-of-life care among patients with esophageal cancer.
502 Background: Esophageal cancer is an aggressive malignancy with a high global prevalence. Patients often suffer from various debilitating symptoms like...
Association between skeletal muscle morphometrics and overall survival among older adults with gastrointestinal cancers.
808 Background: Older adults with gastrointestinal (GI) cancers face a higher risk of treatment toxicities and adverse survival outcomes. However, the var...
The prognostic impact of <i>SLFN11</i> gene expression in metastatic colorectal cancer (mCRC).
254 Background: SLFN11 was recently identified as a dominant determinant of response to DNA-damaging anticancer agents. Several studies showed SLFN11 expr...
A systematic review of the impact of artificial intelligence in pancreatic cancer detection.
685 Background: Pancreatic cancer is the fourth leading cause of cancer deaths in the United States, and early detection remains a significant challenge....
Association between ctDNA levels, timing of blood collection, and overall survival in metastatic colorectal cancer.
245 Background: While circulating tumor DNA (ctDNA) detection is influenced by various factors, the impact of blood collection timing remains understudied...
Organ-specific responses to nivolumab plus ipilimumab in patients with advanced hepatocellular carcinoma: A multicenter, retrospective study.
543 Background: The Check-Mate 9DW trial demonstrated that combining ipilimumab with nivolumab (Ipi/Nivo) improved survival outcomes compared with sorafen...
Safety and tolerability of different total neoadjuvant therapy strategies in patients with locally advanced rectal cancer.
121 Background: Total neoadjuvant therapy (TNT) leads to improved local control and organ preservation for locally advanced rectal cancer (LARC). The chem...
Phase 1/2 study of the trophoblast cell surface antigen 2 (TROP2) antibody-drug conjugate (ADC) sacituzumab tirumotecan (sac-TMT) as monotherapy or combination therapy in gastrointestinal cancers: LIGHTBEAM-02A.
TPS846 Background: There is a significant need for new tolerable and effective therapeutic options for colorectal cancer (CRC), pancreatic ductal adenocar...
Meta-analysis of randomized controlled trials (RCTs) to evaluate the incidence of hemorrhage and venous thromboembolism (VTE) events in patients with gastrointestinal (GI) cancers treated with fruquintinib.
118 Background: Fruquintinib is a novel cancer therapy that was recently approved by the US FDA as a third-line treatment for metastatic colorectal cancer...
Updated results from the trastuzumab deruxtecan (T-DXd) 5.4 mg/kg triplet combination of DESTINY-Gastric03 (DG-03): First-line (1L) T-DXd with fluoropyrimidine (FP) and pembrolizumab in advanced/metastatic HER2-positive (HER2+) esophageal adenocarcinoma, gastric cancer (GC), or gastroesophageal junction adenocarcinoma (GEJA).
448 Background: T-DXd is a HER2-directed antibody-drug conjugate; T-DXd 6.4 mg/kg monotherapy is approved for patients wit...
Therapeutic value of para-aortic lymph node dissection in gastric cancer with extensive lymph node metastasis: Integrated analysis of three phase II trials (JCOG2212A).
419 Background: Gastric cancer (GC) sometimes forms metastatic bulky nodes around celiac artery or its branches (Bulky N), or metastasizes to para-aortic...
Investigating the real-world outcomes of single- versus multi-agent preoperative chemoradiotherapy for locally advanced rectal cancer: NCDB analysis from 2004-2020.
61 Background: Fluorouracil-based chemoradiotherapy is the standard initial treatment for locally advanced rectal cancer, demonstrating improved pathologi...
Incidence trends of early-onset colorectal cancer (EOCRC) in the United States, by age, sex, race and ethnicity, and urbanicity (2000-2021).
26 Background: Research is needed to understand the extent to which the incidence of early onset colorectal cancer (EOCRC)is rising across population sub-...
Perioperative versus adjuvant therapy in resectable pancreas cancer.
703 Background: Pancreatic ductal adenocarcinoma (PDAC) is the third-leading cause of cancer death in the United States with a 5-year survival rate of 13%...
Real-world dose intensity (DI) and time to adverse events (AEs) in a commercial database during first-line (1L) treatment of metastatic pancreatic adenocarcinoma (mPDAC) with FOLFIRINOX (FFX), FFX without 5FU bolus, and gemcitabine + nab-paclitaxel (GnP).
692 Background: Onset of severe AEs during 1L FFX and GnP treatment for mPDAC negatively impacts clinical outcomes, requiring supportive care and/or treat...
Exclusive liver invasion as prognostic indicator in T3 gallbladder cancer.
631 Background: T3 gallbladder cancer (GBC) contains a diverse range of invasive tumors. However, distinct prognostic outcomes may be observed among T3GBC...
First line atezolizumab + bevacizumab (atezo/bev) or durvalumab ± tremelimumab (durva±treme) in unresectable hepatocellular carcinoma (HCC): A real world, multi-institutional retrospective cohort study.
532 Background: HCC accounts for 80% of primary liver cancers, and worldwide, is the third common cause of cancer-related death. Two FDA approved 1st line...
KRAS status in lung oligometastases treated with SBRT.
264 Background: Stereotactic Body Radiotherapy (SBRT) to lung metastases (LM) from colorectal cancer (CRC) has been applied to improve disease control in...
Survival analysis using neoadjuvant rectal score in patients with locally advanced rectal cancer who underwent surgery after neoadjuvant chemoradiotherapy: An ambispective study.
172 Background: Colorectal cancer, the third most common malignancy and a major cause of cancer deaths, is treated using a standard protocol of neoadjuvan...
Obesity and biliary tract cancers: Changing epidemiology.
643 Background: The incidence of biliary tract cancers (BTC) continues to rise (Sung et al. 2024). The reasons remain ill-defined. Over 70% of patients ar...
Annual incidence of colorectal cancer among patients with average risk in the United States between 2017 and 2023.
83 Background: Colorectal cancer (CRC) is the second most common cause of cancer-related mortality and third most common cancer in the United States. In 2...
Disparities in outcomes of pancreatic cancer hospitalizations: A ten-year trend study.
683 Background: Pancreatic cancer is the third leading cause of cancer mortality in the United States with 51,750 estimated deaths from Pancreatic cancer...